Supernus PharmaceuticalsLTS:0LB2 +1.26%88 OCF Yield % is 3.07 as of Jun. 30, 2026, which is 54% below its 10-year median of 6.68. GuruFocus rates LTS:0LB2 with a GF Score™ of 88/100 and a GF Value™ of $40.33 (Modestly Overvalued). Among 1,002 Drug Manufacturers companies, Supernus Pharmaceuticals ranks worse than 52.69% on this metric.
OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Supernus Pharmaceuticals OCF Yield % Related Terms
Supernus Pharmaceuticals OCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0LB2 vs BCRX, PBH, RGC: OCF Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Supernus Pharmaceuticals OCF Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's OCF Yield % distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (LTS:0LB2) has a OCF Yield % of 3.07 as of Jun. 30, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Supernus Pharmaceuticals and its competitors. This is 54% below median its historical median of 6.68. Over the past decade, Supernus Pharmaceuticals' OCF Yield % has ranged from 1.51 to 16.98. According to the industry distribution chart, Supernus Pharmaceuticals ranks #528 out of 1002 companies in the Drug Manufacturers industry, placing it in the top 52.7%.
Is Supernus Pharmaceuticals' OCF Yield % too high?
Supernus Pharmaceuticals' current OCF Yield % of 3.07 is 54% below median its 10-year median of 6.68. Over the past 10 years, this metric has ranged from a low of 1.51 to a high of 16.98. The Drug Manufacturers industry median OCF Yield % is 3.61. Supernus Pharmaceuticals' value of 3.07 is 14.8% below this industry median. Based on the distribution chart, Supernus Pharmaceuticals ranks #528 out of 1002 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Supernus Pharmaceuticals has a GF Score™ of 88/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' OCF Yield % compare to BCRX and PBH?
According to the Drug Manufacturers industry distribution chart, Supernus Pharmaceuticals ranks #528 out of 1002 companies for OCF Yield %. This places Supernus Pharmaceuticals in the lower half of its industry. The industry median OCF Yield % is 3.61. Supernus Pharmaceuticals' value of 3.07 is 14.8% below this benchmark. Historically, Supernus Pharmaceuticals' own OCF Yield % has ranged from 1.51 to 16.98 over the past decade. While the company's 10-year median is 6.68 vs. the industry median of 3.61, Supernus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Drug Manufacturers company?
The median OCF Yield % among Drug Manufacturers companies is 3.61, based on 1,002 companies in the industry. Companies in the top quartile (top 25%) have a OCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Supernus Pharmaceuticals's current OCF Yield % of 3.07 is 14.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on Supernus Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median OCF Yield % is 3.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Supernus Pharmaceuticals's current OCF Yield % is 3.07, which is 54% below median its own 10-year median of 6.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Modestly Overvalued. The stock's GF Value™ is $40.33, compared to a current price of $46.51 — trading 15.3% above its estimated fair value. The current OCF Yield % is 3.07, which is 54% below median its 10-year median of 6.68 and 14.8% below the Drug Manufacturers industry median of 3.61. Supernus Pharmaceuticals' overall GF Score™ is 88/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current OCF Yield % is 3.07 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?
Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be overvalued.
The current stock price of $46.51 is trading 15.3% above its estimated GF Value™ of $40.33.
GuruFocus considers Supernus Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for LTS:0LB2:
OCF Yield %: 3.07 (54% below median its 10-year median of 6.68)
GF Value™: $40.33 vs. price of $46.51 (15.3% above fair value)
Industry Position: 14.8% below the Drug Manufacturers median (#528 of 1002)
No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
88GF Score
Get the complete analysis for LTS:0LB2
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0LB2 has been successfully added to your 
